Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GMP Capital Inc. (GMP.TO) stock logo
GMP
GMP Capital Inc. (GMP.TO)
C$1.62
C$1.07
C$2.39
C$284.97MN/A82,098 shs676,112 shs
NuVista Energy Ltd. stock logo
NVA
NuVista Energy
C$12.83
+0.9%
C$11.71
C$9.59
C$13.72
C$2.66B2.85428,500 shs512,614 shs
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
$0.05
$0.05
$0.25
$3.56
$1.37M2.34455,220 shs4 shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GMP Capital Inc. (GMP.TO) stock logo
GMP
GMP Capital Inc. (GMP.TO)
0.00%0.00%0.00%0.00%0.00%
NuVista Energy Ltd. stock logo
NVA
NuVista Energy
+1.76%+4.87%+10.04%+15.86%+7.44%
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
0.00%0.00%-1.06%+28.28%-99.30%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
GMP Capital Inc. (GMP.TO) stock logo
GMP
GMP Capital Inc. (GMP.TO)
N/AN/AN/AN/AN/AN/AN/AN/A
NuVista Energy Ltd. stock logo
NVA
NuVista Energy
4.1328 of 5 stars
3.40.01.70.03.92.52.5
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
GMP Capital Inc. (GMP.TO) stock logo
GMP
GMP Capital Inc. (GMP.TO)
N/AN/AN/AN/A
NuVista Energy Ltd. stock logo
NVA
NuVista Energy
2.78
Moderate BuyC$15.0317.13% Upside
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
N/AN/AN/AN/A

Current Analyst Ratings

Latest SQZ, GMP, OPHR, NVA, and SEPL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/22/2024
NuVista Energy Ltd. stock logo
NVA
NuVista Energy
CIBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperformC$15.50 ➝ C$16.50
4/19/2024
NuVista Energy Ltd. stock logo
NVA
NuVista Energy
National Bankshares
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector PerformC$14.00 ➝ C$15.00
4/9/2024
NuVista Energy Ltd. stock logo
NVA
NuVista Energy
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOutperformC$17.00
3/22/2024
NuVista Energy Ltd. stock logo
NVA
NuVista Energy
Desjardins
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuyC$15.00 ➝ C$14.75
3/4/2024
NuVista Energy Ltd. stock logo
NVA
NuVista Energy
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetC$14.25 ➝ C$14.50
3/1/2024
NuVista Energy Ltd. stock logo
NVA
NuVista Energy
CIBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperformC$15.00 ➝ C$15.50
2/27/2024
NuVista Energy Ltd. stock logo
NVA
NuVista Energy
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuyC$13.00
(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
GMP Capital Inc. (GMP.TO) stock logo
GMP
GMP Capital Inc. (GMP.TO)
C$19.42M0.00N/A0.21C$1.02 per share0.00
NuVista Energy Ltd. stock logo
NVA
NuVista Energy
C$1.26B2.11N/AN/AC$10.19 per share1.26
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
$18.16M0.08N/AN/A$1.94 per share0.02

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
GMP Capital Inc. (GMP.TO) stock logo
GMP
GMP Capital Inc. (GMP.TO)
N/A-C$0.32N/AN/AN/AN/AN/AN/AN/A
NuVista Energy Ltd. stock logo
NVA
NuVista Energy
C$367.68MC$1.657.780.5929.12%18.16%10.71%5/14/2024 (Estimated)
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
-$79.46M-$2.61N/AN/AN/A-369.96%-119.83%-59.90%N/A

Latest SQZ, GMP, OPHR, NVA, and SEPL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/29/2024Q4 2023
NuVista Energy Ltd. stock logo
NVA
NuVista Energy
C$0.49C$0.41-C$0.08C$0.41C$364.00 millionC$365.50 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
GMP Capital Inc. (GMP.TO) stock logo
GMP
GMP Capital Inc. (GMP.TO)
C$0.05N/AN/AN/A N/A
NuVista Energy Ltd. stock logo
NVA
NuVista Energy
N/AN/AN/AN/AN/A
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
GMP Capital Inc. (GMP.TO) stock logo
GMP
GMP Capital Inc. (GMP.TO)
9.74
1.09
0.80
NuVista Energy Ltd. stock logo
NVA
NuVista Energy
14.42
1.04
0.78
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
N/A
3.50
3.50

Ownership

Institutional Ownership

CompanyInstitutional Ownership
GMP Capital Inc. (GMP.TO) stock logo
GMP
GMP Capital Inc. (GMP.TO)
N/A
NuVista Energy Ltd. stock logo
NVA
NuVista Energy
24.73%
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
38.51%

Insider Ownership

CompanyInsider Ownership
GMP Capital Inc. (GMP.TO) stock logo
GMP
GMP Capital Inc. (GMP.TO)
N/A
NuVista Energy Ltd. stock logo
NVA
NuVista Energy
22.89%
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
16.00%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
GMP Capital Inc. (GMP.TO) stock logo
GMP
GMP Capital Inc. (GMP.TO)
44175.91 millionN/ANot Optionable
NuVista Energy Ltd. stock logo
NVA
NuVista Energy
88207.58 millionN/ANot Optionable
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
5329.49 million24.77 millionNot Optionable

SQZ, GMP, OPHR, NVA, and SEPL Headlines

SourceHeadline
Reviewing BioAtla (NASDAQ:BCAB) and SQZ Biotechnologies (NYSE:SQZ)Reviewing BioAtla (NASDAQ:BCAB) and SQZ Biotechnologies (NYSE:SQZ)
americanbankingnews.com - April 22 at 1:26 AM
VC funding update: who raised money in March?VC funding update: who raised money in March?
bizjournals.com - April 1 at 11:06 AM
SQZ, Portal founder Armon Sharei on starting over in biotechSQZ, Portal founder Armon Sharei on starting over in biotech
biopharmadive.com - March 26 at 10:35 AM
Portal Biotechnologies Announces $5M Pre-Seed Round Led By Pear VCPortal Biotechnologies Announces $5M Pre-Seed Round Led By Pear VC
finance.yahoo.com - March 19 at 10:20 AM
SQZ, months after 80% layoffs, opts for liquidation and $11.8M asset fire sale to StemcellSQZ, months after 80% layoffs, opts for liquidation and $11.8M asset fire sale to Stemcell
fiercebiotech.com - March 1 at 10:56 AM
Rx Rundown: Gilead Sciences, Latigo Biotherapeutics, Exscientia and moreRx Rundown: Gilead Sciences, Latigo Biotherapeutics, Exscientia and more
mmm-online.com - February 16 at 8:05 AM
SQZB SQZ Biotechnologies CompanySQZB SQZ Biotechnologies Company
seekingalpha.com - December 28 at 1:42 PM
SQZ Biotechnologies Co Ordinary Shares SQZBSQZ Biotechnologies Co Ordinary Shares SQZB
morningstar.com - December 12 at 8:37 PM
SQZ founder Armon Sharei opens Portal to to simplify intracellular deliverySQZ founder Armon Sharei opens Portal to to simplify intracellular delivery
fiercebiotech.com - December 12 at 10:35 AM
Medicine at a bigger scale: FUJIFILM Diosynth Biotechnologies unveils new Holly Springs drug manufacturing site'Medicine at a bigger scale': FUJIFILM Diosynth Biotechnologies unveils new Holly Springs drug manufacturing site
wral.com - November 11 at 8:41 PM
‘Difficult but necessary steps’: SQZ lays off 80% of staff, RegenXBio cuts 15%‘Difficult but necessary steps’: SQZ lays off 80% of staff, RegenXBio cuts 15%
fiercebiotech.com - November 9 at 10:34 AM
SQZ Biotechnologies Reports Third Quarter 2023 Financial Results and Recent Portfolio UpdatesSQZ Biotechnologies Reports Third Quarter 2023 Financial Results and Recent Portfolio Updates
finance.yahoo.com - November 8 at 6:33 PM
SQZ Biotechnologies GAAP EPS of -$0.80 misses by $0.30, revenue of $0MSQZ Biotechnologies GAAP EPS of -$0.80 misses by $0.30, revenue of $0M
msn.com - November 8 at 6:33 PM
Lifeline Biotechnologies Inc LLBOLifeline Biotechnologies Inc LLBO
morningstar.com - November 4 at 11:41 PM
SQZ Biotechnologies Reports Data for Clinical Programs at the Society for Immunotherapy of Cancer Annual MeetingSQZ Biotechnologies Reports Data for Clinical Programs at the Society for Immunotherapy of Cancer Annual Meeting
finance.yahoo.com - November 3 at 7:42 PM
SQZ Biotechnologies Reports Second Quarter 2023 Financial Results and Recent Portfolio UpdatesSQZ Biotechnologies Reports Second Quarter 2023 Financial Results and Recent Portfolio Updates
finance.yahoo.com - August 10 at 9:16 PM
Sqz Biotechnologies Co (SQZB)Sqz Biotechnologies Co (SQZB)
investing.com - August 3 at 7:45 AM
Roche declines to take up option on SQZ Bio’s SQZ-APC-HPV programRoche declines to take up option on SQZ Bio’s SQZ-APC-HPV program
thepharmaletter.com - July 27 at 12:11 AM
Roche Passes on Option to Advance Cell Therapy in HPV-Positive Tumors With SQZ BiotechnologiesRoche Passes on Option to Advance Cell Therapy in HPV-Positive Tumors With SQZ Biotechnologies
precisionmedicineonline.com - July 25 at 10:53 PM
Roche Decides Not to Exercise Solid Tumor Option with SQZRoche Decides Not to Exercise Solid Tumor Option with SQZ
biospace.com - July 25 at 10:53 PM
SQZ Biotechnologies Provides Update on Collaboration with RocheSQZ Biotechnologies Provides Update on Collaboration with Roche
benzinga.com - July 25 at 12:37 PM
Roche snubs SQZ HPV 16 programme, leaving the beleaguered company in the lurchRoche snubs SQZ HPV 16 programme, leaving the beleaguered company in the lurch
pharmaceutical-technology.com - July 25 at 12:37 PM
Understanding the Risks of Investing in SQZ Biotechnologies Company (SQZ)Understanding the Risks of Investing in SQZ Biotechnologies Company (SQZ)
knoxdaily.com - July 5 at 1:10 PM
SQZ Biotechnologies to be delisted from the NYSESQZ Biotechnologies to be delisted from the NYSE
seekingalpha.com - July 3 at 11:23 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

GMP Capital Inc. (GMP.TO) logo

GMP Capital Inc. (GMP.TO)

TSE:GMP
GMP Capital Inc., an independent financial services company, provides various financial products and services to corporate clients, institutional investors, and high-net-worth individuals in Canada, the United States, and internationally. It operates in two segments, Operations Clearing and Wealth Management. The Operations Clearing segment provides carrying broker services, including trade execution, clearing, settlement, custody, and other middle and back-office services to Richardson GMP and Stifel Nicolaus Canada Inc. The Wealth Management segment provides wealth management and investment services. GMP Capital Inc. was founded in 1995 and is headquartered in Toronto, Canada.
NuVista Energy logo

NuVista Energy

TSE:NVA
NuVista Energy Ltd., together with its subsidiary, engages in the exploration, development, and production of oil and natural gas reserves in the Western Canadian Sedimentary Basin. The company is involved in the development, delineation, and production of condensate, natural gas liquids, and natural gas reserves. It primarily focuses on the condensate rich Montney formation in the Pipestone and Wapiti areas of the Alberta Deep Basin. The company was incorporated in 2003 and is headquartered in Calgary, Canada.
SQZ Biotechnologies logo

SQZ Biotechnologies

NYSE:SQZ
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.